Buy Bio-Rad

Logo for stock BIO (Bio-Rad)

Amount

£
GBP

Latest price

$297.72
(£1.00 = $1.335)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$8.056B

P/E ratio

27.13

EPS

$11.08

Beta

1.03

Dividend rate

N/A

Dividend yield

N/A

About

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

CEO

Mr. Norman D. Schwartz

Employees

7,700

Sector

Industrials

Company HQ

HERCULES, United States of America

News

Logo for news article #0 (Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.)

Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidiary Medtimo Inc. The move comes post Biorad Medisys' completion of acquisition of business assets from ReShape Lifesciences, a weight loss and metabolic health solutions, and its official rebranding to Medtimo Inc. The investment is in line with Biorad Medisys' intention of seeking growth in regulated markets by expanding its portfolio, enhancing its global reach and curating a sharpened product strategy.

GlobeNewsWire

September 04, 2025

Logo for news article #1 (Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript))

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst Good afternoon. Welcome to the Wells Fargo Healthcare Conference.

Seeking Alpha

September 04, 2025

Logo for news article #2 (Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?)

Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?

BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.

Zacks Investment Research

September 01, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.